BRPI0520677A2 - identificação e caracterização de anticorpos de função de bloqueio anti-ed-b-fibronectina - Google Patents

identificação e caracterização de anticorpos de função de bloqueio anti-ed-b-fibronectina

Info

Publication number
BRPI0520677A2
BRPI0520677A2 BRPI0520677-4A BRPI0520677A BRPI0520677A2 BR PI0520677 A2 BRPI0520677 A2 BR PI0520677A2 BR PI0520677 A BRPI0520677 A BR PI0520677A BR PI0520677 A2 BRPI0520677 A2 BR PI0520677A2
Authority
BR
Brazil
Prior art keywords
fibronectin
characterization
identification
blocking function
function antibodies
Prior art date
Application number
BRPI0520677-4A
Other languages
English (en)
Inventor
Andreas Menrad
Josef Prassler
Armin Weidmann
Original Assignee
Bayer Schering Pharma Ag
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag, Morphosys Ag filed Critical Bayer Schering Pharma Ag
Publication of BRPI0520677A2 publication Critical patent/BRPI0520677A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

IDENTIFICAçãO E CARACTERIZAçãO DE ANTI-CORPOS DE FUNçãO DE BLOQUEIO ANTI-ED-B-FIBRONECTINA. A presente invenção refere-se aos polipeptídeos recombinantes, especialmente aos anticorpos ou fragmentos de anticorpos, que ligam a isoforma ED-B da fibronectina e podem bloquear sua função. Além disso, é publicada a aplicação diagnóstica e farmacêutica dos polipeptídeos de acordo com a invenção.
BRPI0520677-4A 2005-11-09 2005-11-09 identificação e caracterização de anticorpos de função de bloqueio anti-ed-b-fibronectina BRPI0520677A2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2005/012185 WO2007054120A1 (de) 2005-11-09 2005-11-09 Identifizierung und charakterisierung von funktionsblockierenden anti-ed-b-fibronektin antikörpern

Publications (1)

Publication Number Publication Date
BRPI0520677A2 true BRPI0520677A2 (pt) 2009-05-19

Family

ID=36170357

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0520677-4A BRPI0520677A2 (pt) 2005-11-09 2005-11-09 identificação e caracterização de anticorpos de função de bloqueio anti-ed-b-fibronectina

Country Status (8)

Country Link
EP (1) EP1945767B1 (pt)
JP (1) JP2009514540A (pt)
CN (1) CN101356271A (pt)
AT (1) ATE463512T1 (pt)
BR (1) BRPI0520677A2 (pt)
CA (1) CA2628552A1 (pt)
DE (1) DE502005009389D1 (pt)
WO (1) WO2007054120A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
DE10324447A1 (de) 2003-05-28 2004-12-30 Scil Proteins Gmbh Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin
EP1925664A1 (en) 2006-11-15 2008-05-28 Scil proteins GmbH Artificial binding proteins based on a modified alpha helical region of ubiquitin
WO2009102421A2 (en) 2008-02-14 2009-08-20 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins that bind egfr
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
US20120301393A1 (en) 2009-12-14 2012-11-29 Scil Proteins Gmbh Modified ubiquitin proteins having a specific binding activity for the extradomain b of fibronectin
US9562089B2 (en) 2010-05-26 2017-02-07 Bristol-Myers Squibb Company Fibronectin based scaffold proteins having improved stability
WO2012172055A1 (en) 2011-06-15 2012-12-20 Scil Proteins Gmbh Dimeric binding proteins based on modified ubiquitins
WO2012171541A1 (en) 2011-06-15 2012-12-20 Scil Proteins Gmbh Human fusion proteins comprising interferons and hetero-dimeric modified ubiquitin proteins
EP2861616A1 (en) 2012-06-13 2015-04-22 Scil Proteins GmbH Human fusion proteins comprising single chain tnfalpha and targeting domains
WO2014094799A1 (en) 2012-12-19 2014-06-26 Scil-Proteins-Gmbh Ubiquitin moieties as a means for prolonging serum half-life
WO2016124702A1 (en) 2015-02-06 2016-08-11 Scil Proteins Gmbh Novel egfr binding proteins
PL3322721T3 (pl) 2015-07-16 2022-06-06 Navigo Proteins Gmbh Nowe białka wiążące immunoglobulinę i ich zastosowanie w oczyszczaniu na bazie powinowactwa
WO2017013136A1 (en) 2015-07-20 2017-01-26 Scil Proteins Gmbh Novel binding proteins based on di-ubiquitin muteins and methods for generation
WO2017084017A1 (zh) * 2015-11-16 2017-05-26 合肥立方制药股份有限公司 Ed-b蛋白在诊断组织增生中的应用
EP3452097A1 (en) 2016-05-04 2019-03-13 Navigo Proteins GmbH Targeted compounds for the site-specific coupling of chemical moieties comprising a peptide linker
KR102578256B1 (ko) 2016-08-11 2023-09-15 리플리겐 코포레이션 친화성 크로마토그래피를 위한 알칼리 안정 fc-결합 단백질
EP3689903A4 (en) 2017-09-30 2022-01-12 Hefei Lifeon Pharmaceutical Co. Ltd. FIBRONECTIN B DOMAIN BINDING PROTEIN
CA3098444A1 (en) * 2018-04-30 2019-11-07 Viktor Veniaminovich Tets Tetz-proteins and prion-like proteins and associated methods
WO2020006357A1 (en) 2018-06-29 2020-01-02 Tets Viktor Veniaminovich Methods for diagnosis and treatment of type 1 diabetes

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997008320A1 (en) 1995-08-18 1997-03-06 Morphosys Gesellschaft Für Proteinoptimierung Mbh Protein/(poly)peptide libraries
TWI259837B (en) * 1998-05-11 2006-08-11 Eidgenossische Tech Hochscule Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
EP1990409A3 (en) 1999-07-20 2011-05-18 MorphoSys AG Bacteriophage
EP1267935A2 (en) * 2000-01-12 2003-01-02 Light Sciences Corporation Novel treatment for eye disease
EP1259548A1 (en) 2000-02-24 2002-11-27 Eidgenössische Technische Hochschule Zürich Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis
SK2882003A3 (en) 2000-09-07 2003-08-05 Schering Ag Receptor in the EDb fibronectin domain

Also Published As

Publication number Publication date
EP1945767B1 (de) 2010-04-07
CN101356271A (zh) 2009-01-28
DE502005009389D1 (de) 2010-05-20
CA2628552A1 (en) 2007-05-18
WO2007054120A1 (de) 2007-05-18
ATE463512T1 (de) 2010-04-15
JP2009514540A (ja) 2009-04-09
EP1945767A1 (de) 2008-07-23

Similar Documents

Publication Publication Date Title
BRPI0520677A2 (pt) identificação e caracterização de anticorpos de função de bloqueio anti-ed-b-fibronectina
NO20072721L (no) Polypeptides that bind BR3 and uses thereof
BRPI0818437A2 (pt) Anticorpo ou fragmento funcional do anticorpo, composição farmacêutica, uso de pelo menosum dos anticorpos ou fragmentos funcionais dos anticorpos, e, hibridoma
EA200801174A1 (ru) Антитела-миметики glp-2, полипептиды, композиции, способы и применения
WO2006099698A3 (en) Novel anti-plgf antibody
MX2008009886A (es) Anticuerpos que enlazan par-2.
EA200801621A1 (ru) Антитела, направленные на her-3, и их применение
DE602006018424D1 (de) Peptide zum nachweis von ehrlichia ewingii antikörper
DE602006013029D1 (de) Anti-egfr-antikörper
MX2009013824A (es) Proteinas de enlace de antigeno que enlazan par-2.
EA200802348A1 (ru) ЧЕЛОВЕЧЕСКИЙ ВЫСОКОАФФИННЫЙ И ГУМАНИЗИРОВАННЫЙ АНТИ-α5β1 ИНТЕГРИН С ФУНКЦИЕЙ БЛОКИРУЮЩЕГО АНТИТЕЛА С ОСЛАБЛЕННОЙ ИММУНОГЕННОСТЬЮ
ATE497508T1 (de) Gegen das säugetier-eag1-ionenkanalprotein gerichtete antikörper
EA200700847A1 (ru) Материалы, связывающие прионные белки, и способы их применения
TW200738748A (en) Human monoclonal antibody human CD134 (OX40) and methods of making and using same
WO2006086799A3 (en) Prion-specific peptide reagents
WO2007039256A3 (de) Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung
ATE484749T1 (de) Von anti-trichinella-antikörpern erkannte polypeptide und ihre verwendung
WO2006094828A3 (en) Monoclonal antibodies and immunodetection assay specific for the chemotactic epitope of the urokinase-type plasminogen activator receptor
WO2010009856A3 (en) Goodpasture antigen binding protein and its detection
GB0611708D0 (en) Novel antibodies against prion protein and uses thereof
DE602005020147D1 (de) Detektion von verkürzungsmutationen durch massenspektrometrie
MXPA06001287A (es) Identificacion y caracterizacion de anticuerpos anti-ed-b-fibronectina bloqueantes de la funcion.
TR200600421A2 (tr) Fonksiyon bloke eden anti-ED-B-fibronektin antikorların teşhisi ve karakterizasyonu
UY29162A1 (es) Identificación y caracterización de anticuerpos anti-ed-b-fibronectina bloqueantes de la función
CR8222A (es) Identificacion y caracterizacion de anticuerpos anti-ed-b-fibronectina bloqueantes de la funcion

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: MORPHOSYS AG (DE)

Free format text: TRANSFERIDO DE: BAYER SCHERING PHARMA AG

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE A 6A ANUIDADE.

B15K Others concerning applications: alteration of classification

Ipc: C07K 16/18 (2006.01), A61K 39/00 (2006.01), A61P 3